Compare ENGN & TBLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ENGN | TBLD |
|---|---|---|
| Founded | 1999 | 2021 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 605.5M | 647.4M |
| IPO Year | N/A | N/A |
| Metric | ENGN | TBLD |
|---|---|---|
| Price | $9.08 | $20.50 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $22.71 | N/A |
| AVG Volume (30 Days) | ★ 202.6K | 76.1K |
| Earning Date | 12-22-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.12% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.65 | $15.94 |
| 52 Week High | $11.14 | $21.00 |
| Indicator | ENGN | TBLD |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 74.13 |
| Support Level | $8.16 | $20.17 |
| Resistance Level | $9.20 | $20.80 |
| Average True Range (ATR) | 0.63 | 0.28 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 48.51 | 55.55 |
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.